BioCentury
ARTICLE | Clinical News

CRS-207: Ph IIb resumed

December 1, 2016 3:11 AM UTC

Aduro said FDA lifted a partial clinical hold on trials evaluating candidates developed using the company's L. monocytogenes-based immunotherapy construct (LADD) platform. The studies may resume enrollment. Patients in the trials continued to receive treatment during the hold. The agency placed the hold in October after a blood culture sample from a pancreatic cancer patient in Aduro’s Phase IIb ECLIPSE trial of LADD-based vaccine CRS-207 tested positive for Listeria several months after treatment (see BioCentury, Oct. 31)...

BCIQ Company Profiles

Aduro Biotech Inc.